Clinical Report: Breast Cancer Disparities, HPV-Related Cancers, and ICIs

Overview

Recent findings from Roswell Park Comprehensive Cancer Center highlight significant racial disparities in breast cancer outcomes, increased risks of second HPV-related cancers, and cognitive decline associated with immune checkpoint inhibitors (ICIs). These insights were presented at the American Society of Clinical Oncology annual meeting.

Background

Understanding disparities in cancer outcomes is crucial for improving treatment strategies and patient care. The link between HPV and secondary cancers underscores the need for vigilant monitoring in cancer survivors. Additionally, the cognitive effects of ICIs warrant attention as more patients receive these therapies.

Data Highlights

No numerical data available in the source material.

Key Findings

• 83.7% of patients with metastatic HER2-positive breast cancer survived beyond 5 years with antibody-drug conjugates (ADCs).
• Asian patients exhibited the highest survival rates, while Black patients showed the poorest outcomes in breast cancer treatment.
• Survivors of HPV-associated cancers face significantly higher risks of developing second HPV-related cancers compared to the general population.
• Female survivors are at a particularly elevated risk for second cancers, including vaginal, vulvar, and penile cancers.
• Cognitive function declines were most pronounced in women, breast cancer patients, and Black patients under 65 receiving ICIs.

Clinical Implications

Healthcare professionals should consider racial disparities when developing treatment plans for breast cancer patients. Additionally, increased surveillance for second cancers in HPV-related cancer survivors is essential. Awareness of cognitive decline in patients receiving ICIs can guide supportive care strategies.

Conclusion

The findings from Roswell Park emphasize the importance of addressing disparities in cancer care and the need for tailored follow-up strategies for cancer survivors. Ongoing research is vital to improve patient outcomes across diverse populations.

References

1. Roswell Park Comprehensive Cancer Center, Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant, 2023 -- Immune Checkpoint Inhibitors ‘High-Risk Yet Promising’ for Cancer Patients Who Undergo Organ Transplant
2. The ASCO Post, Highlights From the 2021 San Antonio Breast Cancer Symposium Guest Editors, 2021 -- Highlights From the 2021 San Antonio Breast Cancer Symposium
3. The ASCO Post, Dr. Abraham’s Top-10 Picks for the Most Clinically Relevant Breast Cancer Studies of 2015, 2015 -- Dr. Abraham’s Top-10 Picks for the Most Clinically Relevant Breast Cancer Studies of 2015
4. The ASCO Post — Expert Point of View: Priyanka Bhateja, MD Related Articles
5. ENHERTU
6. J Gynecol Oncol. 2026 Jan;37(1):e12
7. Central nervous system complications of immune checkpoint inhibitors: A comprehensive review - ScienceDirect